Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
IRVINE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq:BMRA) (the “Company”) announced that data derived from a clinical study of InFoods® IBS was presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting in a poster titled “IgG-based Elimination Diets for Patients with IBS: Results From a Prospective, Multi-Center, Double-Blind, Placebo-Controlled Trial.” The poster was selected by ACG as a “Presidential Poster.” Fewer than 5% of accepted ACG abstracts each year receive this distinction, which is awarded for high quality, novel and potentially industry disruptive research.
Related news for (BMRA)
- United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use
- MoBot alert highlights: NASDAQ: BTBD, NYSE: NBY, NASDAQ: BMRA, NASDAQ: LCFY, NASDAQ: AIHS (09/03/25 08:00 AM)
- 24/7 Market News Snapshot 03 September, 2025 – BIOMERICA INC (NASDAQ:BMRA)
- United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use
- MoBot’s Stock Market Highlights – 08/14/25 08:00 AM